Biopharma R&D Information &
Custom Report Preparation

La Merie Publishing is an independent business information provider for the biotechnology and pharmaceutical industry. We publish proprietary reports and prepare custom reports.

TOP 25 Pharma Groups in 2017:

Ranking and Analysis by Revenues, Sales, Business Segments, R&D Costs, Operating & Net Income

This free management report prepared by La Merie Publishing contains a compilation and analysis of the key financial data of global Pharma Groups with revenues of more than US$ 10 bln in the fiscal year 2017.

You can download the report TOP 25 Pharma Groups in 2017 by using this link: https://lamerie.com/wp-content/uploads/2019/01/TOP-25-Pharma-Groups-in-2017.pdf

Rankings were established by total revenues, total R&D costs, operating income and net income. Human pharmaceutical sales as well as non-pharma revenues of the TOP 25 Pharma Groups were analyzed by business segments

Methodology:

Financial information is related to the fiscal year 2017 which in most cases corresponds to the calendar year.

Financial information was retrieved in the original currencies as published by the companies in the disclosure documents (press releases, supportive financial information, annual reports, SEC Form 10-K disclosures).

Original currencies (€, GBP, Yen, DKK, CHF) were converted into US$ based on rates of the same day.

“TOP” refers to companies with revenues of more than US$ 10 bln.

Pharma Group” defined as health care company with business segment of pharmaceutical drugs.

Total Human Pharmaceutical sales by definition include prescription/branded/ethical pharmaceuticals, generics/biosimilars, over the counter (OTC) & concumer healthcare (CHC) products and plasma products for use in humans.

Non-Pharma revenues are defined as from other income, royalties & service, vaccines, animal health, contract  manufacturing organization (CMO), crop science, life science, performance materials, diagnostics, devices & instruments and esthetics.

 

Tables